Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Nov 14, 2022
Date Accepted: May 24, 2023
Date Submitted to PubMed: May 26, 2023

The final, peer-reviewed published version of this preprint can be found here:

Comparison of Four Active SARS-CoV-2 Surveillance Strategies in Representative Population Sample Points: Two-Factor Factorial Randomized Controlled Trial

Deckert A, Anders S, Morales I, De Allegrie M, Nguyen HT, Souares A, McMahon S, Meurer M, Burk R, Lou D, Brugnara L, Sand M, Koeppel L, Maier-Hein L, Roß T, Adler T, Brenner S, Dyer C, Herbst K, Ovchinnikova S, Marx M, Schnitzler P, Knop M, Bärnighausen T, Denkinger CM

Comparison of Four Active SARS-CoV-2 Surveillance Strategies in Representative Population Sample Points: Two-Factor Factorial Randomized Controlled Trial

JMIR Public Health Surveill 2023;9:e44204

DOI: 10.2196/44204

PMID: 37235704

PMCID: 10437130

Two-factor factorial randomized multi-arm parallel controlled trial of four SARS-CoV-2 surveillance strategies in representative population sample points

  • Andreas Deckert; 
  • Simon Anders; 
  • Ivonne Morales; 
  • Manuela De Allegrie; 
  • Hoa Thi Nguyen; 
  • Aurélia Souares; 
  • Shannon McMahon; 
  • Matthias Meurer; 
  • Robin Burk; 
  • Dan Lou; 
  • Lucia Brugnara; 
  • Matthias Sand; 
  • Lisa Koeppel; 
  • Lena Maier-Hein; 
  • Tobias Roß; 
  • Tim Adler; 
  • Stephan Brenner; 
  • Christopher Dyer; 
  • Konrad Herbst; 
  • Svetlana Ovchinnikova; 
  • Michael Marx; 
  • Paul Schnitzler; 
  • Michael Knop; 
  • Till Bärnighausen; 
  • Claudia M. Denkinger

ABSTRACT

Background:

Monitoring the SARS-CoV-2 pandemic has so far mainly relied on passive surveillance. However, active surveillance could provide more accurate estimates of the true SARS-CoV-2 prevalence that help to forecast the evolution of the pandemic, enabling evidence-based decision-making.

Objective:

The objective of this study was to compare four different approaches of active SARS-CoV-2 surveillance, focusing on feasibility and epidemiological outcomes.

Methods:

The randomized, two-factorial, multi-arm parallel trial was conducted in 2020 in a German administrative district with approximately 700,000 inhabitants. The epidemiological outcome comprised the SARS-CoV-2 prevalence and its precision. The four study arms combined two factors: i) individuals versus households, ii) direct testing versus testing conditioned on symptom pre-screening. Individuals aged seven years and older were eligible. A total of 27,908 addresses from cluster samples of 51 municipalities were randomly allocated to the arms and 15 consecutive recruitment weekdays. Data collection and logistics were highly digitized, a study website in five languages enabled individual low-barrier registration and tracking of test results. Sample collection kits were sent by post. Participants collected a gargle sample at home and mailed it to the laboratory where it was analyzed with RT-LAMP. Samples with positive/weak RT-LAMP results were confirmed with RT-qPCR.

Results:

The response rates in the four arms varied between 34% and 41%. Altogether, 4,232 persons without pre-screening and 7,623 participating in the pre-screening provided 5,351 gargle samples, of which 5,319 (99%) could be analyzed, yielding 17 confirmed SARS-CoV-2 infections and a combined prevalence of 0.33% (95% CI [0.15%; 0.52%]) in the arms without, respectively 0.04% (95% CI [0.00%; 0.08%]) with pre-screening. Asymptomatic infections occurred in 3/11 positive cases with symptom data. The two arms without pre-screening performed best regarding effectiveness and accuracy.

Conclusions:

This study showed that self-collected gargle samples analyzed with highly sensitive RT-LAMP enable continuous active SARS-CoV-2 surveillance to detect pre- and asymptomatic cases without overburdening PCR capacities and routine diagnostic testing. Efforts to improve participation rates and to facilitate integration into the public health system can increase the potential to effectively monitor the course of the pandemic Clinical Trial: The trial was registered (30/11/2020) at the German Clinical Trials Register, registration number DRKS00023271.


 Citation

Please cite as:

Deckert A, Anders S, Morales I, De Allegrie M, Nguyen HT, Souares A, McMahon S, Meurer M, Burk R, Lou D, Brugnara L, Sand M, Koeppel L, Maier-Hein L, Roß T, Adler T, Brenner S, Dyer C, Herbst K, Ovchinnikova S, Marx M, Schnitzler P, Knop M, Bärnighausen T, Denkinger CM

Comparison of Four Active SARS-CoV-2 Surveillance Strategies in Representative Population Sample Points: Two-Factor Factorial Randomized Controlled Trial

JMIR Public Health Surveill 2023;9:e44204

DOI: 10.2196/44204

PMID: 37235704

PMCID: 10437130

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.